L26/O-153 Tacrolimus improves pregnancy rates after euploid blastocyst transfer in RIF/RPL patients with low regulatory T cells levels
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.151 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von K. Nakagawa und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does tacrolimus improve reproductive outcomes in patients with recurrent implantation failure (RIF) or recurrent pregnancy loss (RPL) who have low regulatory T cells (Treg) levels? Summary answer In euploid blastocyst transfer cycles, tacrolimus treatment for RIF/RPL patients with low Treg levels was associated with higher clinical pregnancy rates. What is known already Successful pregnancy requires maternal immune tolerance towards the semi-allogeneic embryo, a process critically mediated by regulatory T cells. Reduced Treg abundance has been associated with impaired immune tolerance, potentially contributing to implantation failure and early pregnancy loss. However, there are limited data linking Treg deficiency to recurrent implantation failure (RIF) or recurrent pregnancy loss (RPL). Moreover, no standardized, mechanism-based strategy has been established for RIF/RPL patients with low Treg levels. Study design, size, duration This retrospective observational study analyzed euploid blastocyst transfer cycles performed between July 2021 and July 2025. Among 1,161 euploid blastocyst transfer cycles, 320 cycles from refractory cases, patients with ≥3 previous embryo transfers and/or RPL without a live birth, were included if Treg levels were measured prior to embryo transfer. Participants/materials, setting, methods Euploid blastocysts were confirmed by trophectoderm biopsy and next-generation sequencing (NGS); mosaic embryos were excluded. Treg (CD4+CD25+FoxP3+) were measured by flow cytometry during the follicular phase. A cut-off of 6.1 was applied based on a previous data (J Rerpod Immunol 2025). Patients with Treg ≤6.1 received tacrolimus 2–3 mg/day starting 2 days before transfer. Clinical pregnancy was defined by gestational sac (GS); ongoing pregnancy was ≥12 weeks. Main results and the role of chance Data are presented as mean ± SD unless otherwise stated. Among 320 euploid blastocyst transfer cycles, female age was 38.3 ± 3.7 years, male age 40.4 ± 6.1 years, and the number of previous embryo transfers was 6.1 ± 3.7. Clinical pregnancy occurred in 212/320 cycles (66.3%). In logistic regression, higher Treg levels were associated with improved outcomes: each 1-unit increase in Treg levels was linked to higher ongoing pregnancy (OR 1.20, 95% CI 1.02–1.41; p = 0.0029) and lower miscarriage risk (OR 0.57, 95% CI 0.41–0.79; p = 0.0007). The high-Treg group (>6.1; n = 178; mean 7.3 ± 1.0) and the low-Treg group (≤6.1; n = 142; mean 5.1 ± 0.8) showed similar clinical and ongoing pregnancy rates (55.6% and 50.0% vs. 59.9% and 45.1%; p > 0.05, respectively). However, miscarriage was lower in the high-Treg group (10.1% [10/99] vs. 24.7% [21/85]; OR 0.34, 95% CI 0.15–0.78; p = 0.010). Within the low-Treg group, 61 cycles received tacrolimus and 81 did not. Clinical pregnancy was higher with tacrolimus (68.9% vs. 53.1%). After adjustment (female age, prior transfers, endometrial preparation, embryo age), tacrolimus remained associated with higher clinical pregnancy (OR 2.47, 95% CI 1.16–5.27; p = 0.0187), confirmed by IPTW analysis (OR 2.22, 95% CI 1.10–4.45; p = 0.0255). Miscarriage did not differ (31.0% vs. 18.0%; p = 0.779). Limitations, reasons for caution This study included only RIF/RPL patients undergoing euploid embryo transfer, limiting sample size (320 cycles over 4 years). The retrospective design and limited power preclude definitive conclusions regarding miscarriage reduction, warranting larger prospective studies. Wider implications of the findings Lower Treg levels were associated with higher miscarriage risk. In patients showing low Treg levels, tacrolimus was associated with improved clinical pregnancy rate. These findings support immune-etiology stratification and justify prospective trials evaluating tacrolimus in selected RIF/PRL populations. Trial registration number No
Zitieren
APA
Nakagawa, K., Kwak-Kim, J., Shiobara, K., Kataoka, H., Horikawa, T., Maruyama, T., Takamizawa, S., & Sugiyama, R. (2026). L26/O-153 Tacrolimus improves pregnancy rates after euploid blastocyst transfer in RIF/RPL patients with low regulatory T cells levels. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.151
Vancouver
Nakagawa K, Kwak-Kim J, Shiobara K, Kataoka H, Horikawa T, Maruyama T, et al. L26/O-153 Tacrolimus improves pregnancy rates after euploid blastocyst transfer in RIF/RPL patients with low regulatory T cells levels. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.151
BibTeX
@article{Nakagawa2026,
author = {Nakagawa, K. and Kwak-Kim, J. and Shiobara, K. and Kataoka, H. and Horikawa, T. and Maruyama, T. and Takamizawa, S. and Sugiyama, R.},
title = {L26/O-153 Tacrolimus improves pregnancy rates after euploid blastocyst transfer in RIF/RPL patients with low regulatory T cells levels},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.151}
}
EUVIMED